Fortrea Holdings Inc.

NasdaqGS:FTRE Lagerbericht

Marktkapitalisierung: US$1.2b

Fortrea Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Fortrea Holdings wird ein jährliches Gewinn- und Umsatzwachstum von 78.1% bzw. 2.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 76.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.8% betragen.

Wichtige Informationen

78.1%

Wachstumsrate der Gewinne

76.11%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum17.6%
Wachstumsrate der Einnahmen2.8%
Zukünftige Eigenkapitalrendite12.85%
Analystenabdeckung

Good

Zuletzt aktualisiert14 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Narrativ-Update • May 07

FTRE: Execution Risk Around 2026 Revenue Guidance Will Cap Future Upside

Analysts have raised their price targets on Fortrea by $3 to $5, and the fair value estimate in this model has shifted from $5.0 to $9.5 as analysts point to moderating discount rate assumptions, slightly positive revenue growth, and higher expected profit margins reflected in a higher forward P/E multiple. Analyst Commentary Recent research on Fortrea shows a split view, with some firms raising price targets by US$3 to US$5, while others have taken a more cautious stance, trimming targets and questioning how much upside is already reflected in the valuation.
Narrativ-Update • Apr 21

FTRE: Conservative 2026 Guidance And AI Tools May Support Re Rating

The analyst price target for Fortrea has been reset from about $22.59 to $16.00 as analysts factor in updated fair value assumptions, slightly lower revenue growth and profit margin inputs, and a lower future P/E multiple, while also incorporating recent Street research that adjusts targets across firms in response to evolving views on the company's fundamentals and guidance. Analyst Commentary Recent Street research on Fortrea shows a mix of trimmed price targets and selective upgrades, as analysts recalibrate their models around updated guidance and sector views.
Narrativ-Update • Apr 07

FTRE: Margin Recovery Under New Leadership And Conservative 2026 Guidance May Drive Re Rating

Analysts nudged their price target for Fortrea slightly higher to $22.59 from $22.46, citing a mix of higher assumed profit margins, a lower future P/E multiple, and varied recent Street calls that balance upgraded ratings with trimmed targets in the $12 to $22 range. Analyst Commentary Recent Street research on Fortrea shows a wide range of opinions, but the most optimistic voices point to improving execution, clearer profit potential, and room for the shares to rerate as fundamentals stabilize.
Narrativ-Update • Mar 24

FTRE: Margin Recovery And Deleveraging Under New Leadership May Drive Re Rating

Narrative Update The analyst price target for Fortrea has been revised lower from about $25 to roughly $22.46. This reflects analysts balancing recent price target cuts from several banks with more constructive views that cite improving execution, better fundamentals, and a clearer path to margin recovery under new leadership.
Narrativ-Update • Mar 09

FTRE: Margin Recovery And 2026 Guidance Under New Leadership Will Drive Upside

The analyst price target for Fortrea Holdings has shifted lower by about $2 to align with a refreshed fair value estimate of $14.44, as analysts factor in a higher discount rate, more cautious revenue growth assumptions, and only modestly revised margin and P/E inputs, despite recent rating upgrades and mixed target resets across the Street. Analyst Commentary Street research on Fortrea paints a mixed picture, with several firms turning more constructive on execution and earnings power, while others temper expectations for share price upside through lower targets.
Narrativ-Update • Feb 23

FTRE: Execution Improvements And Deleveraging Under New Leadership May Drive Re Rating

Narrative Update on Fortrea Holdings: Analyst Price Target Shift The updated analyst price target for Fortrea Holdings reflects a higher implied valuation in dollar terms. Analysts are citing improved execution under new leadership, a clearer path to margin recovery, and recent target increases from firms that now see better revenue trends, margin potential, and benefits from deleveraging.
Analyseartikel • Feb 12

The Market Doesn't Like What It Sees From Fortrea Holdings Inc.'s (NASDAQ:FTRE) Revenues Yet As Shares Tumble 33%

Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares have retraced a considerable 33% in the last month, reversing a fair...
Narrativ-Update • Feb 09

FTRE: Execution And Margin Recovery Under New Leadership Will Drive Future Upside

Narrative Update: Fortrea Holdings Our updated analyst price target for Fortrea moves higher by about $3, with analysts pointing to improving execution under new leadership, early commercial traction, a clearer path to margin recovery, and more supportive biopharma demand as key reasons for their revised expectations. Analyst Commentary Recent Street research on Fortrea reflects a more constructive tone, with several bullish analysts lifting price targets and upgrading ratings as they reassess the company’s execution, growth prospects, and margin potential.
Narrativ-Update • Jan 25

FTRE: Execution Gains And Biopharma Cycle Tailwinds May Drive Re Rating

Narrative Update on Fortrea Holdings Analysts have lifted their blended price expectations for Fortrea by several dollars, with new targets in the low to mid $20s and up to $25, citing improving execution under new leadership, a clearer path to margin recovery, and better perceived performance as the biopharma cycle picks up. This is broadly consistent with only modest tweaks to our discount rate, revenue growth, margin and future P/E assumptions and no change to our $25.00 fair value estimate.
Narrativ-Update • Jan 11

FTRE: New Leadership And Margin Recovery Path May Drive Re Rating

Analysts have raised their blended price target on Fortrea Holdings to about $25 from roughly $13, reflecting updated assumptions for stronger revenue growth, slightly improved profit margins, and a higher future P/E multiple, alongside recent upgrades and target increases from several firms. Analyst Commentary Bullish analysts are becoming more constructive on Fortrea Holdings, with a series of upgrades and price target increases that highlight improving company execution and a more supportive setup for profitability and valuation.
Narrativ-Update • Dec 27

FTRE: Rapid Share Gains Will Be Tested By Leadership Execution Risks

Analysts have nudged their average price target on Fortrea Holdings higher, from $12.07 to $13.25, citing encouraging early progress under new leadership, a steady Q3 book-to-bill backdrop, and signs that contract research and healthcare utilization trends may be stabilizing into 2026. Analyst Commentary Recent research updates reflect a cautiously constructive stance on Fortrea, with incremental target price hikes tied to operational progress and a stabilizing industry backdrop.
Narrativ-Update • Dec 13

FTRE: Rapid Share Gains Will Face Test From Leadership Transition Execution

Analysts have raised their fair value estimate for Fortrea Holdings from $11.21 to $12.07 per share, citing a lower perceived discount rate, slightly stronger long term revenue growth assumptions, and improving demand signals reflected in multiple recent price target increases across the Street. Analyst Commentary Bullish analysts point to a constructive setup for Fortrea as recent price target increases cluster in a narrow range above the prior consensus, suggesting growing confidence that execution under new leadership can support a re-rating.
Analyseartikel • Dec 07

Fortrea Holdings Inc. (NASDAQ:FTRE) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Despite an already strong run, Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares have been powering on, with a gain of 27...
Narrativ-Update • Nov 29

FTRE: Rapid Share Price Increase Will Challenge Upside Amid Mixed Industry Trends

Analysts have raised their average price target for Fortrea Holdings. Recent targets have moved from approximately $7-11 previously to as high as $14, reflecting improving internal execution, stabilizing industry trends, and cautious optimism regarding future demand.
Seeking Alpha • Nov 20

Fortrea Holdings: Showing Real Signs Of Life

Summary Fortrea Holdings has shown signs of recovery after severe operational and financial struggles, with shares rebounding from historic lows. The company reported improving sales momentum and a rising backlog, but EBITDA and margins remain under pressure, keeping leverage high. Management has implemented cost reductions, raised guidance, and enacted a shareholder rights plan, signaling renewed urgency and insider confidence. While the darkest scenarios seem less likely, conviction to buy remains low; continued monitoring is warranted as recovery progresses. Read the full article on Seeking Alpha
Narrativ-Update • Nov 15

FTRE: Bookings Stability And Leadership Transition Will Shape Outlook Into 2026

Fortrea Holdings' analyst price target has increased significantly from $9.53 to $11.21, as analysts cite a more promising outlook supported by steady bookings, sector stabilization, and improving market demand. Analyst Commentary Recent analyst research highlights both positive developments and ongoing uncertainties for Fortrea Holdings.
Narrativ-Update • Nov 01

FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals

The analyst price target for Fortrea Holdings has been raised from $7 to a range between $9 and $10. Analysts cite stabilizing healthcare cost trends and improving contract research bookings as key factors for their more optimistic outlook.
Narrativ-Update • Oct 18

Global Demographic Trends Will Spur Clinical Advances

Analysts have raised their price target for Fortrea Holdings from $8.30 to $9.44, citing sustained improvements in revenue growth, stabilizing cost trends, and recent industry signals that point to a bottoming in contract research organization demand. Analyst Commentary Recent analyst updates highlight a shifting outlook for Fortrea Holdings, with both optimistic and cautious perspectives emerging from the latest research notes.
Narrativ-Update • Oct 03

Global Demographic Trends Will Spur Clinical Advances

Analysts have raised their fair value estimate for Fortrea Holdings from $7.89 to $8.30 per share. They cite recent improvements in industry bookings and biotech funding, despite continued mixed demand signals.
Narrativ-Update • Sep 05

Global Demographic Trends Will Spur Clinical Advances

The upward revision in Fortrea Holdings’ price target is primarily driven by a lower discount rate, signaling reduced perceived risk and supporting the increase in fair value from $7.44 to $7.89. What's in the News Fortrea Holdings raised its full-year 2025 revenue guidance to $2.6–$2.7 billion.
Analyseartikel • Aug 14

Health Check: How Prudently Does Fortrea Holdings (NASDAQ:FTRE) Use Debt?

NasdaqGS:FTRE 1 Year Share Price vs Fair Value Explore Fortrea Holdings's Fair Values from the Community and select...
Narrativ-Update • Aug 07

Global Demographic Trends Will Spur Clinical Advances

Fortrea Holdings’ price target has been revised upward to $7.02, primarily due to solid earnings visibility and positive physician survey results for hospital segments, despite cost challenges in managed care and a neutral outlook in clinical laboratories. Analyst Commentary Earnings visibility remains solid for hospital-focused segments.
Analyseartikel • Jun 21

Why Fortrea Holdings Inc. (NASDAQ:FTRE) Could Be Worth Watching

Fortrea Holdings Inc. ( NASDAQ:FTRE ), is not the largest company out there, but it led the NASDAQGS gainers with a...
User avatar
Neues Narrativ • May 17

New Therapeutic Areas And AI Adoption Will Fuel Progress

Expanding into therapeutic areas and strengthening partnerships may increase revenue through diversified client engagement.
Analyseartikel • May 08

Is There An Opportunity With Fortrea Holdings Inc.'s (NASDAQ:FTRE) 49% Undervaluation?

Key Insights Fortrea Holdings' estimated fair value is US$11.03 based on 2 Stage Free Cash Flow to Equity Fortrea...
Analyseartikel • Apr 08

Is Fortrea Holdings (NASDAQ:FTRE) Using Debt Sensibly?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Mar 06

Fortrea: A Growing CRO With Strong Backlog, Margin Expansion, And Industry Tailwinds

Summary FTRE's strong backlog of $7.7 billion provides revenue stability and planning advantages, despite short-term spin-off costs and missed earnings. The CRO market is projected to grow significantly, driven by increased outsourcing of complex late-stage trials, positioning FTRE for long-term growth. FTRE's global reach across 90 countries offers a competitive advantage in multi-region trials, enhancing patient enrollment and administrative efficiency. Post-spin-off, FTRE can focus on high-margin areas like oncology and decentralized trials, with expected margin improvements from reduced overhead costs. Read the full article on Seeking Alpha
Analyseartikel • Mar 04

Benign Growth For Fortrea Holdings Inc. (NASDAQ:FTRE) Underpins Stock's 38% Plummet

To the annoyance of some shareholders, Fortrea Holdings Inc. ( NASDAQ:FTRE ) shares are down a considerable 38% in the...
Analyseartikel • Dec 27

We Think Fortrea Holdings (NASDAQ:FTRE) Has A Fair Chunk Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Dec 26

Fortrea: Turning Around As The Activists Move In

Summary Fortrea, a recent Labcorp spin-off, is poised for recovery with strong bookings, industry inflection, and activist interest, despite a 46% stock drop in 2024. CEO Thomas Pike's proven track record and the potential January Effect add to Fortrea's upside, targeting a $45 stock price within a year. The CRO industry's temporary downturn is reversing, with Fortrea's book-to-bill ratio improving to 1.23x, indicating strong future revenue growth. Fortrea's high leverage and ongoing spin-off expenses are concerns, but activist involvement and potential acquisition post-July 2025 offer additional upside. Read the full article on Seeking Alpha
Seeking Alpha • Nov 28

Fortrea: Some Green Shoots After A Dismal Period

Summary Fortrea faces challenges with falling sales, lack of earnings, and high leverage, despite some positive signs in the third quarter. The company, spun off from Labcorp, operates in an interesting CRO sector, yet results are underwhelming. While leverage remains high, potential EBITDA improvements and reduced separation costs offer a roadmap for future growth, but risks like AI disruption remain. Read the full article on Seeking Alpha
Analyseartikel • Nov 21

There Is A Reason Fortrea Holdings Inc.'s (NASDAQ:FTRE) Price Is Undemanding

Fortrea Holdings Inc.'s ( NASDAQ:FTRE ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy...

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:FTRE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20282,806-171631679
12/31/20272,693-4612213411
12/31/20262,607-75795511
3/31/20262,709-447190221N/A
12/31/20252,723-98688114N/A
9/30/20252,760-1,028-132N/A
6/30/20252,734-1,030-103-88N/A
3/31/20252,686-755145164N/A
12/31/20242,696-271237263N/A
9/30/20242,709-246226264N/A
6/30/20242,748-244233268N/A
3/31/20242,811-119111145N/A
12/31/20232,843-32128168N/A
9/30/20232,89550129178N/A
6/30/20232,943127196257N/A
3/31/20233,01116887146N/A
12/31/20222,8371462883N/A
12/31/20213,05898143170N/A
12/31/20202,580-359177201N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: FTRE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: FTRE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: FTRE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: FTREDie Einnahmen des Unternehmens (2.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).

Hohe Wachstumseinnahmen: FTREDie Einnahmen des Unternehmens (2.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: FTREDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.8%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/22 14:35
Aktienkurs zum Tagesende2026/05/22 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Fortrea Holdings Inc. wird von 13 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Eric ColdwellBaird
Luke SergottBarclays
Michael RyskinBofA Global Research